Cervical cancer remains a primary cause of female death in developing countries, but its prognosis can be greatly improved if patients are diagnosed earlier. In the present study, we screened the common differentially expressed genes (DEGs) of cervical squamous cell carcinoma (CESC) from dataset GSE7803, Gene Expression Omnibus, and The Cancer Genome Atlas databases. An integrated bioinformatics analysis was performed based on these DEGs for their enrichment in functions and pathways, interaction network, prognostic signature, and candidate molecular drugs. As a result, 164 (114 upregulated and 47 downregulated) DEGs of CESC were identified for further investigation. We then conducted the gene ontology term enrichment and Kyoto Encyclopedia of Genes and Genomes Pathway analyses to reveal the underlying functions and pathways of these DEGs. In the protein–protein interaction network, hub module and hub genes were identified. Five genes of significant prognostic value—DSG2, ITM2A, CENPM, RIBC2, and MEIS2—were identified by prognostic signature analysis and used to construct a risk linear model. Further validation and investigation suggested DSG2 might be a key gene in CESC prognosis. We then identified two candidate small molecules (trichostatin A and tanespimycin) against CESC. Further validation and exploration of these hub genes are warranted for future prospect in clinical applications.
Get full access to this article
View all access options for this article.
References
1.
BasilicoF., MaffiniS., WeirJ.R., PrumbaumD., RojasA.M., ZimniakT., et al. (2014). The pseudo GTPase CENP-M drives human kinetochore assembly. Elife, 3, e2978.
2.
BrennanD., and MahoneyM.G. (2009). Increased expression of DSG2 in malignant skin carcinomas: A tissue-microarray based study. Cell Adh Migr, 3, 148–154.
3.
CaiF., ZhuQ., MiaoY., ShenS., SuX., and ShiY. (2017). Desmoglein-2 is overexpressed in non-small cell lung cancer tissues and its knockdown suppresses NSCLC growth by regulation of p27 and CDK2. J Cancer Res Clin Oncol, 143, 59–69.
4.
CastagneR., ZellerT., RotivalM., SzymczakS., TruongV., SchillertA., et al. (2011). Influence of sex and genetic variability on expression of X-linked genes in human monocytes. Genomics, 98, 320–326.
5.
ChandrashekarD.S., BashelB., BalasubramanyaS., CreightonC.J., Ponce-RodriguezI., ChakravarthiB., et al. (2017). UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia, 19, 649–658.
6.
ChenJ., AronowB.J., and JeggaA.G. (2009). Disease candidate gene identification and prioritization using protein interaction networks. BMC Bioinformatics, 10, 73.
7.
ClarkeC., MaddenS.F., DoolanP., AherneS.T., JoyceH., O'DriscollL., et al. (2013). Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis, 34, 2300–2308.
8.
DayR.S., McDadeK.K., ChandranU.R., LisovichA., ConradsT.P., HoodB.L., et al. (2011). Identifier mapping performance for integrating transcriptomics and proteomics experimental results. BMC Bioinformatics, 12, 213.
9.
DehmerM., MuellerL.A., and Emmert-StreibF. (2013). Quantitative network measures as biomarkers for classifying prostate cancer disease states: a systems approach to diagnostic biomarkers. PLoS One, 8, e77602.
10.
EkeI., and CordesN. (2015). Focal adhesion signaling and therapy resistance in cancer. Semin Cancer Biol, 31, 65–75.
11.
ErlichmanC. (2009). Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs, 18, 861–868.
12.
GaliliT., O'CallaghanA., SidiJ., and SievertC. (2018). Heatmaply: an R package for creating interactive cluster heatmaps for online publishing. Bioinformatics, 34, 1600–1602.
13.
GautierL., CopeL., BolstadB.M., and IrizarryR.A. (2004). affy—analysis of Affymetrix GeneChip data at the probe level. Bioinformatics, 20, 307–315.
14.
Gornowicz-PorowskaJ., Bowszyc-DmochowskaM., Seraszek-JarosA., KaczmarekE., and DmochowskiM. (2011). Loss of correlation between intensities of desmoglein 2 and desmoglein 3 expression in basal cell carcinomas. Acta Dermatovenerol Croat, 19, 150–155.
15.
GrossA., SchulzC., KolbJ., KosterJ., WehnerS., CzaplinskiS., et al. (2018). Tumorigenic and antiproliferative properties of the TALE-transcription factors MEIS2D and MEIS2A in neuroblastoma. Cancer Res, 78, 1935–1947.
16.
HajjiN., WallenborgK., VlachosP., NymanU., HermansonO., and JosephB. (2008). Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells. Oncogene, 27, 3134–3144.
17.
HoshibaT. (2018). An extracellular matrix (ECM) model at high malignant colorectal tumor increases chondroitin sulfate chains to promote epithelial-mesenchymal transition and chemoresistance acquisition. Exp Cell Res, 370, 571–578.
18.
IrizarryR.A., HobbsB., CollinF., Beazer-BarclayY.D., AntonellisK.J., ScherfU., et al. (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics, 4, 249–264.
19.
KangJ., SergioC.M., SutherlandR.L., and MusgroveE.A. (2014). Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer, 14, 32.
20.
KauffmanS.A. (1969). Metabolic stability and epigenesis in randomly constructed genetic nets. J Theor Biol, 22, 437–467.
21.
KimS.J., NakayamaS., ShimazuK., TamakiY., AkazawaK., TsukamotoF., et al. (2012). Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers. Ann Oncol, 23, 891–897.
22.
KimW.T., SeoS.P., ByunY.J., KangH.W., KimY.J., LeeS.C., et al. (2018). The anticancer effects of garlic extracts on bladder cancer compared to cisplatin: a common mechanism of action via centromere protein M. Am J Chin Med, 46, 689–705.
23.
LaiC.K., NorddahlG.L., MaetzigT., RostenP., LohrT., SanchezM.L., et al. (2017). Meis2 as a critical player in MN1-induced leukemia. Blood Cancer J, 7, e613.
24.
LiJ.M., and BrooksG. (1999). Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy?. Eur Heart J, 20, 406–420.
25.
LiuJ., NieS., GaoM., JiangY., WanY., MaX., et al. (2019). Identification of EPHX2 and RMI2 as two novel key genes in cervical squamous cell carcinoma by an integrated bioinformatic analysis. J Cell Physiol, 234, 21260–21273.
26.
MusaA., GhoraieL.S., ZhangS.D., GlazkoG., Yli-HarjaO., DehmerM., et al. (2018). A review of Connectivity Map and computational approaches in pharmacogenomics. Brief Bioinform, 19, 506–523.
27.
NanniniM., PantaleoM.A., MaledduA., AstolfiA., FormicaS., and BiascoG. (2009). Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev, 35, 201–209.
28.
NapierC., MitchellA.L., GanE., WilsonI., and PearceS.H. (2015). Role of the X-linked gene GPR174 in autoimmune Addison's disease. J Clin Endocrinol Metab, 100, E187–E190.
29.
NguyenT.M., ShinI.W., LeeT.J., ParkJ., KimJ.H., ParkM.S., et al. (2016). Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer. Gynecol Oncol, 140, 545–553.
30.
PeglionF., LlenseF., and Etienne-MannevilleS. (2014). Adherens junction treadmilling during collective migration. Nat Cell Biol, 16, 639–651.
31.
PengD.H., UngewissC., TongP., ByersL.A., WangJ., CanalesJ.R., et al. (2017). ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis. Oncogene, 36, 1925–1938.
32.
PetryszakR., BurdettT., FiorelliB., FonsecaN.A., Gonzalez-PortaM., HastingsE., et al. (2014). Expression Atlas update—a database of gene and transcript expression from microarray- and sequencing-based functional genomics experiments. Nucleic Acids Res, 42, D926–D932.
RamaniV.C., HenningsL., and HaunR.S. (2008). Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer. BMC Cancer, 8, 373.
35.
RanganathanP., and RangnekarV.M. (2005). Exploiting the TSA connections to overcome apoptosis-resistance. Cancer Biol Ther, 4, 391–392.
36.
RhodesD.R., Kalyana-SundaramS., MahavisnoV., VaramballyR., YuJ., BriggsB.B., et al. (2007). Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia, 9, 166–180.
37.
RitchieM.E., PhipsonB., WuD., HuY., LawC.W., ShiW., et al. (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 43, e47.
38.
RobinsonM.D., McCarthyD.J., and SmythG.K. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics, 26, 139–140.
39.
SaaberF., ChenY., CuiT., YangL., MireskandariM., and PetersenI. (2015). Expression of desmogleins 1–3 and their clinical impacts on human lung cancer. Pathol Res Pract, 211, 208–213.
40.
SaitohM. (2018). Involvement of partial EMT in cancer progression. J Biochem, 164, 257–264.
41.
SalvaticiM., AchilarreM.T., SandriM.T., BoveriS., VannaZ., and LandoniF. (2016). Squamous cell carcinoma antigen (SCC-Ag) during follow-up of cervical cancer patients: role in the early diagnosis of recurrence. Gynecol Oncol, 142, 115–119.
42.
ShannonP., MarkielA., OzierO., BaligaN.S., WangJ.T., RamageD., et al. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res, 13, 2498–2504.
43.
SiegelR.L., MillerK.D., and JemalA. (2016). Cancer statistics, 2016. CA Cancer J Clin, 66, 7–30.
44.
SubramanianA., KuehnH., GouldJ., TamayoP., and MesirovJ.P. (2007). GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics, 23, 3251–3253.
45.
SzklarczykD., FranceschiniA., WyderS., ForslundK., HellerD., Huerta-CepasJ., et al. (2015). STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res, 43, D447–D452.
46.
TanL.Y., MintoffC., JohanM.Z., EbertB.W., FedeleC., ZhangY.F., et al. (2016). Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. Oncotarget, 7, 46492–46508.
47.
TangZ., LiC., KangB., GaoG., LiC., and ZhangZ. (2017). GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res, 45, W98–W102.
48.
ThorenoorN., Faltejskova-VychytilovaP., HombachS., MlcochovaJ., KretzM., SvobodaM., et al. (2016). Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer. Oncotarget, 7, 622–637.
49.
UhlenM., FagerbergL., HallstromB.M., LindskogC., OksvoldP., MardinogluA., et al. (2015). Proteomics. Tissue-based map of the human proteome. Science, 347, 1260419.
50.
VasioukhinV. (2012). Adherens junctions and cancer. Subcell Biochem, 60, 379–414.
51.
YashiroM., NishiokaN., and HirakawaK. (2006). Decreased expression of the adhesion molecule desmoglein-2 is associated with diffuse-type gastric carcinoma. Eur J Cancer, 42, 2397–2403.
52.
YuG., WangL.G., HanY., and HeQ.Y. (2012). clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS, 16, 284–287.
53.
ZeestratenE.C., MaakM., ShibayamaM., SchusterT., NitscheU., MatsushimaT., et al. (2012). Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer. Br J Cancer, 106, 133–140.
54.
ZhaY., XiaY., DingJ., ChoiJ.H., YangL., DongZ., et al. (2014). MEIS2 is essential for neuroblastoma cell survival and proliferation by transcriptional control of M-phase progression. Cell Death Dis, 5, e1417.
55.
ZhangP., KawakamiH., LiuW., ZengX., StrebhardtK., TaoK., et al. (2018). Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer. Mol Cancer Res, 16, 378–389.
56.
ZhangR., ShiH., RenF., ZhangM., JiP., WangW., et al. (2017). The aberrant upstream pathway regulations of CDK1 protein were implicated in the proliferation and apoptosis of ovarian cancer cells. J Ovarian Res, 10, 60.
57.
ZhangW., LiuY., ZhaoN., ChenH., QiaoL., ZhaoW., et al. (2015). Role of Cdk1 in the p53-independent abrogation of the postmitotic checkpoint by human papillomavirus E6. J Virol, 89, 2553–2562.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
